Loading clinical trials...
Loading clinical trials...
Operational Research for Cryptococcal Antigen Screening to Improve ART Survival
This will be a stepped wedge randomized trial design to evaluate the implementation of cryptococcal antigen (CRAG) screening and preemptive anti-fungal therapy of HIV-infected persons entering antiretroviral therapy (ART) outpatient treatment in Uganda. Those who are ART eligible with a CD4≤100 cells/mcL will have a serum/plasma CRAG performed by lateral flow assay. Those who are CRAG-positive and asymptomatic will be treated with high dose fluconazole. After 6 months survival with retention-in-care will be compared between those who are CRAG+ and CRAG negative
Age
14 - No limit years
Sex
ALL
Healthy Volunteers
No
Infectious Disease Institute, Makerere University
Kampala, Uganda
Kampala Capital Council Authority Clinics
Kampala, Uganda
Start Date
July 1, 2012
Primary Completion Date
June 1, 2015
Completion Date
June 1, 2015
Last Updated
June 4, 2020
3,049
ACTUAL participants
Fluconazole
DRUG
Lead Sponsor
University of Minnesota
Collaborators
NCT05685641
NCT03002012
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions